Changeflow GovPing Government General Class I Recall: UDENYCA (pegfilgrastim-cbqv) Te...
Urgent Enforcement Amended Final

Class I Recall: UDENYCA (pegfilgrastim-cbqv) Temperature Abuse - Lot 2199821

Favicon for changeflow.com FDA Drug Recalls (Class I)
Filed
Detected
Email

Summary

FDA has classified a Class I recall of UDENYCA (pegfilgrastim-cbqv) injection 6mg/0.6mL prefilled syringes distributed by McKesson. The recall affects 116 cartons of Lot 2199821 (expires 05/31/2027) with 116 specific serial numbers due to temperature abuse. The affected product was stored at controlled room temperature instead of the required refrigerated environment. FDA classified this as a Class I recall on 2026-02-26. The recall was initiated by the firm on 2026-01-16 and is ongoing.

Published by FDA on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

FDA has classified a Class I drug recall of UDENYCA (pegfilgrastim-cbqv) injection 6mg/0.6mL single-dose prefilled syringes. The affected product includes 116 cartons from Lot 2199821 with specific serial numbers, which were stored at controlled room temperature instead of the required refrigerated environment, constituting temperature abuse. The recall was initiated by the firm on January 16, 2026 and classified by FDA as Class I on February 26, 2026.

Healthcare providers and patients who have received UDENYCA with the affected serial numbers should immediately cease use and return the product to McKesson. Class I recalls represent the most serious category, indicating reasonable probability that use of the product will cause adverse health consequences or death. The recall affects product nationwide in the United States.

What to do next

  1. Cease use and distribution of affected UDENYCA cartons with specific serial numbers
  2. Return recalled product to McKesson

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

McKesson

Drug Recalls (Class I)

← All Drug Recalls (Class I) Class I D-0353-2026 · 20260218 · Ongoing · Voluntary: Firm initiated

Product

UDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, NDC 69448...

Reason for Recall

Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.

Affected Lot Numbers / Codes

Subset of Lot 2199821, Expires: 05/31/2027 Specific Serial Numbers being Recalled: 160R694TT06X; 1C74A686RPPG; 1W6A2M777N3V; 20825394KR8P; 242E2RK3EA92; 2DG49VH89EPG; 2WEA2ADK1P4H; 3KR2TVAG3VDH; 42M0V0G9PM84; 46E9XKDPTH1R; 4AM12WEAE48H; 4FGHR096DMNV; 4MWGWM991XNA; 4NEW8XD9DNM2; 4Y2PYDFN9YA1; 61EPX42R4K2A; 63FN9VW5CAV7; 69TG160DW2CV; 69XFP3TMTP7X; 6AWVDCNHTV61; 6CEFY72W5GPA; 6FHF1A59X0X4; 6GA64FNDVGXY; 6NW5FACPPWDW; 75V19CF2A0PA; 7HK7155YNAK3; 7R51VVA1WX9T; 7XCKXMH2EERC; 85D8MFVM66D4; 8F3Y5NFFHC64; 8RDWKPM53N5R; 8W1PVXC5NAFW; 9338DPED7P3R; 9A4CXFTGCPYN; 9FKN5NRDX99A; 9G79AR0RGAY4; 9K28G80GGYXN; 9NN7NXE40M13; A48PXEPE77YE; A8M168K58G64; AMR0RNWHTWMW; AR145NW8WTVX; AY19W6DEGRX4; C276HMDGRE49; CAY0ARAEGMCF; CKT370X2G4NP; D0DFAXCN6G5W; D54TXR8AD9Y8; DAK3XP1P3DMP; DH44AGKTX27F; E69E9K6C29VD; EK1D8P703RCH; EX947FYVW7Y6; F2K148YVNRDD; F4EVX8573F1V; FEXA7MENKWF1; FNDNMPAFH89D; G2W3WTMP5HK9; G5MN0F418FFY; G6XECANG6P01; G7FNVGWW3D72; GAHFFNX336GA; GKNTDP4AV6AA; GVPN5C4D23H6; GVPPYARK1FCD; GVXDAAA87GA1; GX7AP73W4HMH; HDTFT2W59K52; HDVG3W6VW59Y; HP703MKWGGM7; K8CGDV1301TP; KN6Y35T0A198; KVGC92YVC6XF; KYCP1Y7CK4R4; MEY2VW5MC0N9; MGH40F2679X3; N11XGETGDAVM; N9DGTY65NFGN; NH9VM1K2ECGP; NNCFT59RD1KF; NVFCXRWHX93N; P3XY0RNV0VPY; P609NH6W670V; P9Y7926YN82A; PA88CCXMWCMG; PKADTN18YR1X; PM0YHNNK6P4T; R11TYM5VE9CK; R45AXAEK4TTN; R6C3533P943P; RMW35MXX4R4K; RX75F9DA58W4; RXRCRP9272DG; RXTH041DMT5D; T2FW4C24F364; T442NHDFD7H8; TC3443DCR4F8; TK8TRR8NT92A; TT8K21TGYFWY; V255NE533X59; V6MYKEA7HN7P; V764DEYM4RYP; VCPTYV1EF0R1; VECGDTDV1Y3A; VEE09A07R9X5; VEER64AW2C51; VRN2TE3HPK5N; WF14WA03FNT2; WTP5TKRGNFGW; WWPMXV50FRM4; X1DKP0T2AE1W; X59C5AV3VDTG; XKG3T7811TD2; Y0CYY950EYK8; YCRW0EPK620Y; YNYA64T18DPW.

Quantity

116 cartons

Firm Notification Method

E-Mail

Distribution

Nationwide in the USA

Initiated

20260116

FDA Classified

20260226

Sources: openFDA · Raw JSON

Get daily alerts for FDA Drug Recalls (Class I)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
January 16th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0353-2026

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug recall response Temperature-sensitive storage Pharmaceutical distribution
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Product Safety Healthcare

Get alerts for this source

We'll email you when FDA Drug Recalls (Class I) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!